Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Autor:	Ikeda K; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan. ikedakenji@tora.email.ne.jp.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan. ikedakenji@tora.email.ne.jp., Kawamura Y; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Kobayashi M; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Kominami Y; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Fujiyama S; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Sezaki H; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Hosaka T; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Akuta N; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Saitoh S; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Suzuki F; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Suzuki Y; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Arase Y; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan., Kumada H; Department of Hepatology, Toranomon Hospital, Toranomon 2-2-2, Minato-ku, Tokyo, 105-8470, Japan.; Okinaka Memorial Institute of Medical Research, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Digestive diseases and sciences [Dig Dis Sci] 2017 Oct; Vol. 62 (10), pp. 2932-2942. Date of Electronic Publication: 2017 Sep 07.
DOI:	10.1007/s10620-017-4739-z
Abstrakt:	Background: Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC). Patients and Methods: A total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2-10 times. Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy. Results: HCC recurrence rates at the end of first and second year were 18.1 and 22.1% in patients with once of HCC therapy, 28.2 and 41.6% in those with 2-3 times of therapy, and 60.2 and 74.5% in those with 4 or more times of therapy, respectively (P < 0.0001). Recurrence rates were compared between 89 patients with DAA therapy after initial HCC therapy and 89 age-, gender-, and BCLC staging-matched patients without antiviral therapy after initial HCC therapy. HCC recurrence rates at first and second year were 18.1 and 25.0% in patients with DAA therapy and 21.8 and 46.5% in those without DAA therapy, respectively (P = 0.003). Multivariate analysis showed DAA therapy significantly decreased recurrence rate with a hazard ratio of 0.353 (confidence interval: 0.191-0.651) after adjustment with covariates of tumor multiplicity, alpha-fetoprotein value, and prothrombin time. Conclusions: DAA therapy significantly decreased recurrence rate when it was performed after initial HCC therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink